Design, Synthesize and Biological Evaluation of Novel Urea Soluble Epoxide Hydrolase Inhibitors

Soluble Epoxide Hydrolase (sEH) enzyme converts Epoxyeicosatrienoic acids (EETs), substrates formed by epoxygenases from arachidonic acid, to the corresponding diols. EETs have a wide range of physiological effects. Among them, vasodilatory actions in vascular conduit, renal afferent arterioles, and coronary vessels are more considerable and lead to the regulation of blood pressure and myocardial perfusion. In addition, EETs modulate adhesion molecule expression, platelet aggregation, vascular smooth muscle cell migration, and thrombolytic properties, which could be involved in a protective mechanism against athero 5 sclerosis. Therefore, sEH inhibition that leads to the accumulation of active EETs, provides a novel approach to the treatment of hypertension and atherosclerosis. Since the most reported potent sEH inhibitors have limited pharmacokinetic profile, they aren’t useful for clinical application. The effort to achieve to sEH inhibitors with proper potency and enhanced pharmacokinetic properties is still continuous. In this study, new urea-based compounds with oxadiazole ring against sEH enzyme were developed. The designed compounds showed a high affinity to the active site of the sEH enzyme and were synthesized in good yield and characterized by IR, Mass, and 1HNMR. Some novel compounds had comparable in vitro sEH inhibitory activity to 12-(3-Adamantan-1-yl-ureido)-dodecanoicacid (AUDA), a potent urea-based sEH inhibitor.